报告类别： **示范实验室数据报告**

质控品名： **肿瘤标志物液体非定值质控品Plus**

REF	512-1	6×3mL	EXP	2021-11-20	LOT	30D6F4F	更新日期：	2020-11

		批号：30D6F4F	
项目\仪器\试剂\方法	单位	均值	+ / - 2 SD
(AFP)甲胎蛋白			
Beckman Access Dedicated \ Chemiluminescence Immunoassay (CLIA)	ng/mL	11.8	9.4-14.2
Roche cobas E601/602 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	10.7	8.5-12.9
Caris200 WanTai(BeiJin) \ Chemiluminescence Immunoassay (CLIA)	ng/mL	9.22	7.38-11.1
(CA 125)糖类抗原 125			
Caris200 WanTai(BeiJin) \ Chemiluminescence Immunoassay (CLIA)	IU/mL	44.6	35.7-53.5
Beckman Access Dedicated \ Chemiluminescence Immunoassay (CLIA)	IU/mL	23.5	18.7-28.3
Roche cobas E601/602 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	IU/mL	35.6	28.4-42.8
(CA 15-3)糖类抗原 15-3			
Beckman Access Dedicated \ Chemiluminescence Immunoassay (CLIA)	IU/mL	16.6	13.2-20
Roche cobas E601/602 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	IU/mL	28.6	22.8-34.4
Caris200 WanTai(BeiJin) \ Chemiluminescence Immunoassay (CLIA)	IU/mL	23.9	19.1-28.7
(CA 19-9)糖类抗原 19-9			
Beckman Access Dedicated \ Chemiluminescence Immunoassay (CLIA)	IU/mL	35.4	28.2-42.6
Roche cobas E601/602 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	IU/mL	25.3	20.1-30.5
(CA 72-4)糖类抗原 72-4			
Roche cobas E601/602 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	IU/mL	5.72	4.52-6.92
Caris200 WanTai(BeiJin) \ Chemiluminescence Immunoassay (CLIA)	IU/mL	9.46	7.57-11.4
Roche Hitachi/Hitachi Systems Roche \ Electro-Chemiluminescence Immunoassay (ECLIA)	IU/mL	5.95	4.75-7.15
(CEA)癌胚抗原			
Caris200 WanTai(BeiJin) \ Chemiluminescence Immunoassay (CLIA)	ng/mL	3.53	2.82-4.24
Beckman Access Dedicated \ Chemiluminescence Immunoassay (CLIA)	ng/mL	4.51	3.57-5.45
Roche cobas E601/602 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	4.06	3.24-4.88
(Cyfra 21-1)细胞角蛋白19片段			
Roche Hitachi/Hitachi Systems Roche \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	4.79	3.81-5.77
Caris200 WanTai(BeiJin) \ Chemiluminescence Immunoassay (CLIA)	ng/mL	4.71	3.77-5.65
Roche cobas E601/602 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	4.76	3.8-5.72
(Ferritin)铁蛋白			
Roche cobas 4000/6000/8000 Roche \ Immunoturbidimetry (ITA)	μg/L	26.7	21.3-32.1
Caris200 WanTai(BeiJin) \ Chemiluminescence Immunoassay (CLIA)	μg/L	26.1	20.9-31.3
Beckman Access Dedicated \ Chemiluminescence Immunoassay (CLIA)	μg/L	20.1	15.9-24.3
(F-PSA)游离前列腺特异性抗原			
Caris200 WanTai(BeiJin) \ Chemiluminescence Immunoassay (CLIA)	ng/mL	0.35	0.28-0.42
Beckman Access Dedicated \ Chemiluminescence Immunoassay (CLIA)	ng/mL	0.56	0.44-0.68
Roche cobas E601/602 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	0.32	0.2-0.44

报告类别： **示范实验室数据报告**

质控品名： **肿瘤标志物液体非定值质控品Plus**

REF	512-1	6×3mL	EXP	2021-11-20	LOT	30D6F4F	更新日期：	2020-11

		批号：30D6F4F	
项目\仪器\试剂\方法	单位	均值	+ / - 2 SD
(hCG)人绒毛膜促性腺激素			
Beckman Access Dedicated \ Chemiluminescence Immunoassay (CLIA)	IU/L	5.95	4.75-7.15
(NSE)神经元特异性烯醇化酶			
Roche cobas E601/602 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	0.98	0.78-1.18
Roche Hitachi/Hitachi Systems Roche \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	0.949	0.749-1.15
(PSA)前列腺特异性抗原			
Beckman Access Dedicated \ Chemiluminescence Immunoassay (CLIA)	ng/mL	2.31	1.81-2.81
Roche cobas E601/602 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	2.8	2.22-3.38
Caris200 WanTai(BeiJin) \ Chemiluminescence Immunoassay (CLIA)	ng/mL	1.74	1.39-2.09
(Tg)甲状腺球蛋白			
Beckman Access Dedicated \ Chemiluminescence Immunoassay (CLIA)	ng/mL	4.79	3.81-5.77
Roche cobas E601/602 Dedicated \ Electro-Chemiluminescence Immunoassay (ECLIA)	ng/mL	7.1	5.64-8.56
(β2M)β-2-微球蛋白			
Siemens BN II Dedicated \ Chemiluminescence Immunoassay (CLIA)	mg/L	6	4.8-7.2
Caris200 WanTai(BeiJin) \ Chemiluminescence Immunoassay (CLIA)	mg/L	5.29	4.23-6.35
Roche cobas c 501/502/701/702 Roche \ Immunoturbidimetry (ITA)	mg/L	4.62	3.68-5.56
(β-hCG)人绒毛膜促性腺激素β亚基			
Roche cobas E601/602 Roche \ Electro-Chemiluminescence Immunoassay (ECLIA)	IU/L	5.25	4.19-6.31

注：此报告所提供的数据均基于检测相同批号质控品的若干实验室的数据汇总统计而来，仅供学习、参考之用。因所用技术、仪器和试剂的不同，或因制造商检测方法的改变，均可导致实验室实际测得的数据偏离此报告所提供的数据。根据良好实验室规范的要求，实验室须遵循相关技术规范确立自己的均值和可接受范围。